In breast cancer, a prospective, randomized, phase II study showed that the combination of rh - endostatin with chemotherapy produced a higher tumor response rate without increasing toxicity in breast cancer patients, but the sample size was relatively small (30). The gene discussed is COL18A1; the disease is breast carcinoma.